Directors of the California stem cell
agency this Wednesday will be asked to approve initiation of a $40 million, high-risk research program aimed at filling “key gaps”
in knowledge about human stem cell behavior.
The staff proposal calls
for as many as 30 awards, but did not specify a limit on the total dollars for each award. The competition is open to both business and academics
and non-profit organizations.
The proposal said that the round is
targeting “high-risk, exploratory pursuits.” The goal is to fill
“key gaps in our understanding of fundamental human stem cell
behaviors that hinder the pace of discovery, and ultimately prevent
the potential of this research from being fully realized.”
The CIRM proposal laid out the following
objectives that were prompted by an “external review” two years
ago.
- “Attract Follow-On Financing and
Co-funding of CIRM Funded Research - “Support of Company
Creation/Growth/Relocation - “Early Engagement of Top Tier
Biopharmaceutical Companies in Order to Access Critical Expertise - “Assume a Leadership Role in
Business Related Areas the are Critical for Supporting the Field”
The CIRM memo listed a number of
initiatives that the agency has already started and said more are
expected to come. They include the already enacted, new business-friendly
award program, the recent hire of an unidentified business
development officer, designation of industry “collaborators,”
relocation support for high impact companies and participation with
industry in developing “reimbursement pathways” that will benefit
the regenerative medicine industry.
“Reimbursement” is the euphemistic
term that industry prefers instead of saying “beefing up profits.”
Last week,
the report by the Institute of Medicine, which cost CIRM $700,000, noted that biotech firms have
received only about 6 percent of the $1.7 billion handed out by CIRM,
a figure not mentioned by the eight-year-old agency's industry
engagement plan.
The IOM said that industry
representation on the agency's critical, decision-making boards (the governing board and standards and
grant reveiew groups) should be enhanced. Additionally, a new scientific advisory
board with substantial industry presence should be created to replace
existing advisory groups. All of which would be aimed at enhancing
and leveraging industry “expertise and resources in product
development, manufacturing, and regulatory approval in support of
the ultimate goal of bringing therapies to patients,” according to
the IOM.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Mq5Z-PgI3cY/40-million-high-risk-stem-cell-research.html
Recommendation and review posted by G. Smith